An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Legend Biotech Announces Appointment of Chief Medical Officer
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) has appointed Mythili Koneru, M.D., Ph.D. as its new Chief Medical Officer. Dr. Koneru previously served at Marker Therapeutics where she led the development of cell therapies and peptide vaccines. Her extensive background includes roles at Eli Lilly, focusing on immuno-oncology clinical development, and an oncology fellowship at Memorial Sloan-Kettering Cancer Center. CEO Ying Huang expressed confidence in Dr. Koneru's expertise in immunotherapy and cell therapy, emphasizing her role in advancing the company's pipeline. Dr. Koneru holds a B.A. in Cellular and Molecular Biology from the University of Chicago, a Ph.D. in Tumor Immunology from New York University, and an M.D. from Robert Wood Johnson Medical School.
Positive
Dr. Koneru brings extensive experience in immunotherapy and cell therapy.
Her leadership is expected to advance the company's clinical development and innovation.
Negative
Transitioning to a new CMO may cause temporary disruptions in ongoing projects.
SOMERSET, N.J.--(BUSINESS WIRE)--
Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Mythili Koneru, M.D., Ph.D. as the Company’s Chief Medical Officer. In this role, Dr. Koneru will be responsible for overseeing the Company’s clinical development and medical affairs programs.
Dr. Koneru joins Legend Biotech from Marker Therapeutics, where she served as Chief Medical Officer, leading the development of the company’s cell therapies and peptide vaccines in its immuno-oncology portfolio. Prior to her time at Marker Therapeutics, Dr. Koneru served as Associate Vice President of Immuno-Oncology at Eli Lilly and Company, where she focused on the clinical development of immuno-oncology assets in the company’s early phase oncology portfolio. Prior to Eli Lilly, Dr. Koneru was an Oncology Fellow at Memorial Sloan-Kettering Cancer Center, where she developed adoptive T-cell therapies in both leukemia and solid tumor malignancies in early phase clinical trials.
“On behalf of the Company, I am pleased to welcome Dr. Koneru to the Legend team,” said Ying Huang, CEO of Legend Biotech. “Dr. Koneru brings a wealth of knowledge in the field of immunotherapy and cell therapy, with extensive experience in designing early-stage clinical trials for hematologic malignancies and solid tumors. We look forward to her leadership and contributions to our organization, as we continue to advance our pipeline of cell-based therapies and bring innovative therapies to clinic.”
Dr. Koneru obtained her B.A. in Cellular and Molecular Biology from the University of Chicago, a Ph.D. in Biomedical Research: Tumor Immunology from New York University, and an M.D. from Robert Wood Johnson Medical School.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Who is the new Chief Medical Officer of Legend Biotech?
Mythili Koneru, M.D., Ph.D. is the newly appointed Chief Medical Officer of Legend Biotech.
What experience does Mythili Koneru bring to Legend Biotech?
Dr. Koneru has a background in developing cell therapies and peptide vaccines, previously serving as CMO at Marker Therapeutics and in various roles at Eli Lilly and Memorial Sloan-Kettering.
What is the expected impact of Dr. Koneru's appointment on Legend Biotech?
Her appointment is anticipated to enhance the company's clinical development efforts and support the advancement of its therapeutic pipeline.
Legend Biotech Corporation American Depositary Shares
